Synta Pharmaceuticals Corp. (NASDAQ:SNTA)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on discovering, developing and commercializing small molecule drugs that address severe medical conditions with potential markets, including cancer and chronic inflammatory diseases.

Results 1 - 20 of 29 : 1 2 Next »

Recs

0
Member Avatar pchop123 (79.60) Submitted: 7/18/2014 6:41:03 PM : Outperform Start Price: $4.11 SNTA Score: -4.09

watch their Ph III Study

Recs

0
Member Avatar superstar (98.98) Submitted: 7/3/2014 10:39:52 AM : Outperform Start Price: $4.43 SNTA Score: -10.72

SNTA currently has a Phase 3 study of ganetespib in combination with docetaxel versus docetaxel alone in patients with advanced non-small-cell lung adenocarcinoma. Ganetespib may also prove successful in treating breast cancer, and ovarian cancer -- and some early stage trials are taking place there as well. I like the pipeline at SNTA, and the company appears undervalued compared to its peers. I made a real purchase at $4.50.

Recs

0
Member Avatar swingtrader858 (45.05) Submitted: 5/12/2014 8:01:58 PM : Outperform Start Price: $4.23 SNTA Score: -14.42

HUGE insider purchases. A great sign for a biopharm or biotech company. Buying in the $4's provides a great risk/reward ratio, as so much support plus insider purchases at these levels. Target $6 by end of 2014.

Recs

0
Member Avatar vutilolo (< 20) Submitted: 5/8/2014 10:21:24 AM : Outperform Start Price: $4.20 SNTA Score: -10.78

We are at all-time lows here. With SNTA selling stock @ 4.01 to a large holder, we all have the chance here to pick up this stock @ "employee pricing". Long term win!

Recs

0
Member Avatar OKwarrior (32.00) Submitted: 4/20/2014 12:29:51 PM : Outperform Start Price: $3.99 SNTA Score: -6.94

This is a roller coaster ride, high risk, higher (I hope) returns. They are burning through cash, but unlike a lot of zombie biotechs, they do have a chance of hitting the big one.

I am green thumbing it now only d/t the charts which suggest it is near the bottom of a trading range. Of course Custer thought it was just a couple of scouts on the ridge at Little Big Horn.

Recs

1
Member Avatar zzlangerhans (99.77) Submitted: 4/19/2014 3:43:40 PM : Outperform Start Price: $3.99 SNTA Score: -6.94

The great thing about rating Synta is that red or green, you're likely to get a positive score eventually. This stock has had more ups and downs than the elevator at the Empire State Building. Every time the company looks like it's finally knocked out, it comes roaring back with a new lead drug. Every time Synta looks like it's finally hit the big time, it gets splattered.

These days traders are disappointed with uninspiring ganetespib data from GALAXY-1 and ENCHANT, but interpretations of data from early stage oncology trials can be fluid. Meanwhile, Synta is advancing ganetespib into new trials for new indications. A heavy cash burn adds to the suspense as Synta scrambles for hard evidence that ganetespib has commercial potential before having to run to the capital markets hat in hand once again.

Despite my sixteen prior positive CAPS bets on Synta, I have yet to trade the stock in real life. Perhaps this green thumb will mark the time when I finally leverage my hours of work on reviewing Synta into trading profits.

Recs

0
Member Avatar TerryFool (< 20) Submitted: 3/25/2014 5:50:51 AM : Outperform Start Price: $4.35 SNTA Score: -15.06

BUY@ 4.1 TP 15

Recs

0
Member Avatar TerryHoodSr (52.03) Submitted: 3/12/2014 12:06:13 PM : Outperform Start Price: $4.27 SNTA Score: -14.30

SPEC BP 4.3 TP 7.0

Recs

0
Member Avatar CountDaBean (78.07) Submitted: 2/16/2014 3:07:05 AM : Outperform Start Price: $6.32 SNTA Score: -45.02

New drug in trials. Expect shares to jump to 10.00 a share if trials are successful

Recs

0
Member Avatar diablo138 (< 20) Submitted: 1/12/2014 12:53:38 PM : Outperform Start Price: $6.50 SNTA Score: -47.05

Lot's of medicine in the pipeline, great outlook for this company!

Recs

0
Member Avatar jpokergman (< 20) Submitted: 11/18/2013 5:39:35 PM : Outperform Start Price: $4.98 SNTA Score: -31.00

big insider buy....that's why.

Recs

0
Member Avatar ssanaka (< 20) Submitted: 6/16/2013 10:19:00 AM : Outperform Start Price: $4.09 SNTA Score: -23.77

possible blockbuster lung cancer drug in the pipeline

Recs

0
Member Avatar frankyz669 (< 20) Submitted: 9/3/2010 10:23:24 AM : Outperform Start Price: $2.92 SNTA Score: -44.37

Magic Formula - though speculative. I think it made the MF list because of huge cash infusion from selling its position with another partner.

Recs

0
Member Avatar smith972 (83.48) Submitted: 4/21/2010 5:30:50 PM : Outperform Start Price: $4.04 SNTA Score: -67.51

I'll watch SNTA in caps here.

Recs

1
Member Avatar cibient (21.35) Submitted: 2/4/2010 1:14:38 PM : Outperform Start Price: $4.08 SNTA Score: -87.92

Surge of insider buying inspires confidence. While this means nothing if the drug ultimately doesn't fly, or heavy dilution tramples existing shareholders, the company has a good balance sheet due to the recent capital raise.

Recs

0
Member Avatar aulden1954 (< 20) Submitted: 1/15/2010 7:51:08 PM : Outperform Start Price: $4.84 SNTA Score: -92.84

Their product base has started rough with the cancer drug but, they have good products in the pipe line that is giving some positive light on the companies pipe line of products.

I like my chances because the company has many other products they are bringing to market. If they only bring one to market and get bough out they have become a success haven't they.

Recs

0
Member Avatar iddqkfyou (< 20) Submitted: 1/13/2010 7:37:20 AM : Outperform Start Price: $4.63 SNTA Score: -88.61

Insiders just (Jan.) purchased 5+% of the company at this price. Insiders do not buy millions of their own biotech company without good reason.

Recs

0
Member Avatar dgu004 (96.14) Submitted: 12/22/2009 5:00:32 AM : Underperform Start Price: $6.50 SNTA Score: +117.06

Went too high before the trail is successful. Red ink will show again for the quarters to come.

Recs

0
Member Avatar TuffPicks (< 20) Submitted: 9/22/2009 12:17:50 PM : Outperform Start Price: $3.15 SNTA Score: -59.09

wallstreet buy list

Recs

0
Member Avatar ChicagoBreeze (< 20) Submitted: 10/23/2008 3:41:04 PM : Outperform Start Price: $5.72 SNTA Score: -156.60

Promising risky microcap biotech for various types of cancer with phase 3 interium results later out this year. One person described this as possiblly the "next celgene". Also has high insider ownership. NO insiders have sold since it went public nearly 2 years ago.

Results 1 - 20 of 29 : 1 2 Next »

Featured Broker Partners


Advertisement